Companies expect to commence first-in-human studies of Trx-1 in ovarian cancer in 1H15 Yale researchers present the latest in vitro and in vivo results at Drug Discovery and Therapy 2014 World Congress , today announced the success of proof-of-concept pre-clinical studies confirming the potency of experimental drug, Trx-1, in the treatment of ... (more)
http://ift.tt/1lx1KYC
http://ift.tt/1lx1KYC
No comments:
Post a Comment